tecentriq
Top Ten most popular articles on Pharmafile.com this week
March 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Cancer, GSK, Hemlibra, MSD, Roche, Sun Pharma, Takeda, brexit, pharma, tecentriq, top ten
As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …
Roche’s Tecentriq improves OS in first-line lung cancer
March 26, 2018Research and Development, Sales and Marketing Roche, biotech, drugs, lung cancer, pharma, pharmaceutical, tecentriq
Roche has revealed further data from its Phase 3, IMpower150 study, which showed that a combination of Tecentriq and Avastin, …
Roche’s immunotherapy improves PFS but unclear long-term benefit in lung cancer
March 20, 2018Manufacturing and Production, Research and Development Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
Roche’ Tecentriq needs a big result in the immunotherapy space – it initially burst onto the scene as a third-to-market …
Roche Tecentriq combo effective, but is it enough?
December 8, 2017Medical Communications, Research and Development Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival …
Roche unveils strong combination treatment data in lung cancer
November 20, 2017Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq
Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …
Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer
September 27, 2017Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq
It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …
FDA locks down combo immunotherapy trials, Roche added to hold
September 19, 2017Manufacturing and Production, Sales and Marketing Roche, biotech, drugs, immunotherapy, pharma, pharmaceutical, tecentriq
The FDA has moved to ensure that all immunotherapy trials studying PD-1/L1 agents, alongside immunomodulatory medicines in certain blood cancers …
Roche blockbuster immunotherapy Tecentriq outclassed by chemo in latest trial
May 10, 2017Research and Development, Sales and Marketing Roche, tecentriq
It has been revealed that Roche’s immuno-oncology drug Tecentriq (atezolizumab) has failed to hit its primary endpoint in a follow-up …
Roche’s drug scores expanded FDA indication in advanced bladder cancer
April 18, 2017Manufacturing and Production, Sales and Marketing Genentech, Roche, tecentriq
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded indication in the US after …
Immunotherapy: The three major treatments that are changing cancer prognoses
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …
Genentech oncology head leaves for Bellicum CEO role
February 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bellicum, Genentech, Roche, tecentriq
Bellicum Pharmaceuticals has snatched up Genentech’s Rick Fair as its new CEO and President. Fair moves to Bellicum from Genentech …
MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme
January 25, 2017Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq
Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …
Roche’s Tecentriq scores another bladder cancer Priority Review
January 9, 2017Sales and Marketing Roche, bladder cancer, tecentriq
Roche has announced that its immunotherapy drug Tecenetriq (atezolizumab) has been awarded Priority Review by the FDA for the treatment …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
